MedeliX
Start asking

alogliptin/pioglitazone

Incresync · ATC code A10BD09

Also known as: Alogliptin/Pioglitazon, Alogliptin / Pioglitazone

Key facts
Active substance
alogliptin/pioglitazone (INN: alogliptin / pioglitazone)
Drug class
Anti-diabetic medication
ATC code
A10BD09
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Incresync 12.5 mg/30 mg film-coated tablets / Incresync 25 mg/30 mg film-coated tablets / Incresync 25 mg/45 mg film-coated tablets
Marketing authorisation holder
Takeda Pharma A/S
Information as of
2026-10-28

Key facts

Alogliptin/pioglitazone (Incresync) is a fixed combination of a DPP-4 inhibitor and a thiazolidinedione used to lower blood glucose in type 2 diabetes.

What it is used for

  • Type 2 diabetes in adults aged 18 years and older as second- or third-line treatment, adjunct to diet and exercise: when inadequately controlled on pioglitazone alone and metformin is inappropriate, or in combination with metformin (triple therapy).
  • Replacement of separate alogliptin and pioglitazone tablets in patients already on this combination.
  • Response (e.g. HbA1c) should be reviewed after 3 to 6 months and treatment discontinued if inadequate.

Dosing

  • One tablet of 25 mg/30 mg or 25 mg/45 mg once daily, depending on the pioglitazone dose already being taken; when combined with metformin, the metformin dose is maintained.
  • Maximum daily dose 25 mg alogliptin and 45 mg pioglitazone.
  • Moderate renal impairment (CrCl ≥30 to ≤50 mL/min): one tablet of 12.5 mg/30 mg once daily; not recommended in severe renal impairment (CrCl < 30 mL/min) or dialysis.
  • Must not be used in hepatic impairment. In advanced age, alogliptin dosing should be conservative because of possible reduced renal function.
  • Once daily with or without food; a missed dose should be taken when remembered, but not a double dose on the same day.

Contraindications

  • Hypersensitivity to the active substances or excipients, or a serious hypersensitivity reaction (e.g. anaphylaxis, angioedema) to any DPP-4 inhibitor.
  • Cardiac failure or history of cardiac failure (NYHA stages I to IV).
  • Hepatic impairment.
  • Diabetic ketoacidosis.
  • Current or past bladder cancer; uninvestigated macroscopic haematuria.

Important warnings

  • Pioglitazone can cause fluid retention and may exacerbate or precipitate heart failure; watch for weight gain and oedema, especially in combination with insulin.
  • Bladder cancer was reported more frequently with pioglitazone; macroscopic haematuria should be investigated before starting, and patients should report blood in the urine or urinary urgency.
  • Acute pancreatitis: discontinue if suspected and do not restart if confirmed.
  • Periodic monitoring of liver enzymes; hepatic dysfunction including hepatic failure has been reported.
  • Increased hypoglycaemia risk in triple therapy with metformin; increased bone fracture rate in women; bullous pemphigoid can occur with DPP-4 inhibitors.
  • Not for use in type 1 diabetes.

Side effects

  • Common: upper respiratory tract infections, sinusitis, headache, hypoglycaemia, nausea, weight increase, oedema, pruritus, bone fracture.
  • Serious (alogliptin component): acute pancreatitis and hypersensitivity reactions such as Stevens-Johnson syndrome, anaphylaxis and angioedema.
  • Women taking pioglitazone had more fractures (2.6% vs 1.7% with comparator).

Interactions

  • Gemfibrozil (a CYP2C8 inhibitor) increases pioglitazone AUC 3-fold; the pioglitazone dose may need to be decreased.
  • Concomitant insulin or NSAIDs may increase the risk of oedema and heart failure.

Pregnancy and breastfeeding

  • Should not be used during pregnancy.
  • A risk to the breast-fed child cannot be excluded; a decision on breast-feeding or therapy is required.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • IncresyncTakeda Pharma A/S · EMEA/H/C/002178

Source: European Medicines Agency (EMA), product information

Brand names in 3 more European countries
Iceland
Incresync
Liechtenstein
Incresync
Norway
Incresync

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Incresync – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/incresync-epar-product-information_en.pdf
  2. Wikidata (CC0): ATC A10BD.

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.